enGene (NASDAQ:ENGN – Get Free Report) is one of 439 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare enGene to similar businesses based on the strength of its valuation, dividends, analyst recommendations, profitability, earnings, institutional ownership and risk.
Valuation and Earnings
This table compares enGene and its competitors gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -3.34 |
enGene Competitors | $156.02 million | -$17.55 million | 117.28 |
enGene’s competitors have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Dividends
Insider and Institutional Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 30.8% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 22.6% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares enGene and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,893.41% | -127.11% | -24.51% |
Risk & Volatility
enGene has a beta of -0.63, suggesting that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s competitors have a beta of 1.21, suggesting that their average share price is 21% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for enGene and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 734 | 2347 | 5545 | 66 | 2.57 |
enGene presently has a consensus price target of $34.40, suggesting a potential upside of 531.19%. As a group, “Biotechnology” companies have a potential upside of 15.99%. Given enGene’s stronger consensus rating and higher probable upside, research analysts clearly believe enGene is more favorable than its competitors.
Summary
enGene beats its competitors on 10 of the 15 factors compared.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.